Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Hydrocortisone Sodium Phosphate

FDA-approved product (injectable, injection), marketed as Hydrocortone.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Hydrocortisone Sodium Phosphate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Adrenal gland disease
  • Adrenocortical insufficiency
  • Allergic conjunctivitis
  • Asthma
  • Atopic eczema
  • Bursitis
  • Cancer
  • Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency
  • Congenital adrenal hyperplasia
  • Crohn's disease
  • Dermatitis
  • Endocrine system disease
  • Exanthem
  • Eye inflammation
  • Hemorrhoid
  • Herpes Labialis
  • and 19 more

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Corticosteroids for local oral treatment; Corticosteroids acting locally; Corticosteroids; Corticosteroids, weak (group i); Corticosteroids, weak, other combinations
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA52.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli30.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae25.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis31.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Hydrocortisone Sodium Phosphate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.6 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.2 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.4 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Hydrocortisone Sodium Phosphate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Bortezomib With Chemotherapy for Relapsed Pediatric Acute Lymphoblastic Leukemia (ALL)

    NCT00440726 · start 2006-08-04

    Registered record
    Registry ID
    NCT00440726
    Conditions
    Acute Lymphoblastic Leukemia
    Interventions
    Bortezomib; Dexamethasone; PEG-asparaginase; Doxorubicin; Cytarabine; Methotrexate; Vincristine; Triple IT Therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2006-08-04
    Completion
    2011-02-26
    Enrolment
    31

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Lymphoblastic Leukemia
    InterventionBortezomib; Dexamethasone; PEG-asparaginase; Doxorubicin +4 more
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • The Importance of Adrenomedullin (AM) on ACTH-Cortisol-Glucose Axis

    NCT00459511 · start 2006-01

    Registered record
    Registry ID
    NCT00459511
    Conditions
    Systemic Inflammatory Response Syndrome; Hyperglycemia
    Interventions
    Blood AM, IL-6, ACTH, Cortisol, Glucose and Insulin
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2006-01
    Completion
    2006-10
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSystemic Inflammatory Response Syndrome; Hyperglycemia
    InterventionBlood AM, IL-6, ACTH, Cortisol, Glucose and Insulin
    PhaseNot recorded
    Registry statusCompleted

  • Corticosteroid Therapy of Septic Shock - Corticus

    NCT00147004 · start 2002-03

    Registered record
    Registry ID
    NCT00147004
    Conditions
    Shock, Septic
    Interventions
    hydrocortisone sodium succinate; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2002-03
    Completion
    2005-11
    Enrolment
    500

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionShock, Septic
    Interventionhydrocortisone sodium succinate; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome

    NCT00002798 · start 1996-08

    Registered record
    Registry ID
    NCT00002798
    Conditions
    Childhood Acute Erythroleukemia (M6); Childhood Acute Megakaryocytic Leukemia (M7); Childhood Acute Monoblastic Leukemia (M5a); Childhood Acute Monocytic Leukemia (M5b); Childhood Acute Myeloblastic Leukemia With Maturation (M2); Childhood Acute Myeloblastic Leukemia Without Maturation (M1); Childhood Acute Myelomonocytic Leukemia (M4); Childhood Myelodysplastic Syndromes; Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndromes; Refractory Anemia; Refractory Anemia With Excess Blasts; Refractory Anemia With Excess Blasts in Transformation; Refractory Anemia With Ringed Sideroblasts; Secondary Myelodysplastic Syndromes; Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies
    Interventions
    asparaginase; daunorubicin hydrochloride; fludarabine phosphate; therapeutic hydrocortisone; allogeneic bone marrow transplantation; 3-dimensional conformal radiation therapy; filgrastim; cytarabine; idarubicin; dexamethasone; thioguanine; etoposide; methotrexate; cyclophosphamide; aldesleukin; busulfan
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    1996-08
    Completion
    Not recorded
    Enrolment
    880

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChildhood Acute Erythroleukemia (M6); Childhood Acute Megakaryocytic Leukemia (M7); Childhood Acute Monoblastic Leukemia (M5a); Childhood Acute Monocytic Leukemia (M5b) +12 more
    Interventionasparaginase; daunorubicin hydrochloride; fludarabine phosphate; therapeutic hydrocortisone +12 more
    PhasePhase 3
    Registry statusCompleted

  • Three Drug Combination Therapy Versus Conventional Treatment of Children With Congenital Adrenal Hyperplasia

    NCT00001521 · start 1995-06-08

    Registered record
    Registry ID
    NCT00001521
    Conditions
    Congenital Adrenal Hyperplasia (CAH)
    Interventions
    Fludrocortisone; Hydrocortisone; Letrozole; Flutamide; Testolactone
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    1995-06-08
    Completion
    2024-04-01
    Enrolment
    66

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCongenital Adrenal Hyperplasia (CAH)
    InterventionFludrocortisone; Hydrocortisone; Letrozole; Flutamide +1 more
    PhasePhase 3
    Registry statusCompleted